» Articles » PMID: 31136970

Epithelial-to-mesenchymal Transition: Event and Core Associates in Bladder Cancer

Overview
Specialty Biology
Date 2019 May 29
PMID 31136970
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Urothelial carcinoma of the bladder (UCB) shows different biological outcomes, diverse biological propensities for invading the muscularis as well as epithelial-to-mesenchymal transition (EMT), a dynamic key event during developmental processes, wound healing, and tissue repair. The EMT core molecules include EMT-activating transcription factors (EMT-ATFs), and a host of downstream effectors and target genes including extracellular inducers and growth factors. Here, we describe molecular regulatory determinants of mesenchymal-to-epithelial transition (MET) and more specifically EMT that allows a subset of urothelial cancer cells to gain mesenchymal traits with self-renewal potential. EMT accelerates tumor progression and poses a clinical challenge to anticancer therapies. Targeting the populations of tumor-initiating cells and those with a metastable phenotype provide the basis for the development of more reliable risk assessment of tumor progression and risk, and better treatment strategies of UCB.

Citing Articles

An immune biomarker associated with EMT serves as a predictor for prognosis and drug response in bladder cancer.

Jiang Y, Yu Z, Zheng H, Zhou X, Zhou M, Geng X Aging (Albany NY). 2024; 16(13):10813-10831.

PMID: 38980253 PMC: 11272103. DOI: 10.18632/aging.205927.


Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes.

Wu J, Zhang F, Zheng X, Chen D, Li Z, Bi Q Sci Rep. 2024; 14(1):14431.

PMID: 38910160 PMC: 11194261. DOI: 10.1038/s41598-024-65198-8.


ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder Cancer though Sarcosine Production.

Kishi S, Mori S, Fujiwara-Tani R, Ogata R, Sasaki R, Ikemoto A Int J Mol Sci. 2023; 24(22).

PMID: 38003554 PMC: 10671720. DOI: 10.3390/ijms242216367.


Down-regulation and clinical significance of Sorbin and SH3 domain-containing protein 1 in bladder cancer tissues.

Li S, Zhai G, He R, Chen G, Wang S, Liu J IET Syst Biol. 2023; 17(2):70-82.

PMID: 36854874 PMC: 10116029. DOI: 10.1049/syb2.12060.


Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.

Zhang Z, Yu Y, Li P, Wang M, Jiao W, Liang Y Front Immunol. 2022; 13:954616.

PMID: 35958586 PMC: 9359097. DOI: 10.3389/fimmu.2022.954616.